Breast cancer incidence after risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers

Cancer Prevention Research

Volumn 5, Issue 11, 2012, Pages 1291-1297

  Fakkert, Ingrid E ^a   Mourits, Marian J E ^a   Jansen, Liesbeth ^a   Van Der Kolk, Dorina M ^a   Meijer, Kees ^a   Oosterwijk, Jan C ^a   Van Der Vegt, Bert ^a   Greuter, Marcel J W ^a   De Bock, Geertruida H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCING SALPINGOOOPHORECTOMY; RISK REDUCTION; SALPINGOOOPHORECTOMY;

ADULT; BREAST NEOPLASMS; CARCINOMA; COHORT STUDIES; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; INCIDENCE; MIDDLE AGED; MUTATION; NETHERLANDS; OVARIECTOMY; RISK FACTORS; RISK REDUCTION BEHAVIOR; SALPINGOSTOMY;

EID: 84870184800     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0190     Document Type: Article

References (33)

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Loman N, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30. (Pubitemid 36530000)
2. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33. (Pubitemid 46706879)
3. van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJ, de Vries J, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 2010;124:643-51.
4. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427-37.
5. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365: 1769-78.
6. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004;292:1317-25. (Pubitemid 39223222)
7. Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005;23:8469-76.
8. Hagen AI, Kvistad KA, Maehle L, Holmen MM, Aase H, Styr B, et al. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 2007;16:367-74. (Pubitemid 47157808)
9. Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hulla JA, Massuger LF, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007;96:1335-42. (Pubitemid 46685786)
10. van der Velde NM, Mourits MJ, Arts HJ, de Vries J, Leegte BK, Dijkhuis G, et al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer 2009;124:919-23.
11. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80-7.
12. Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 2005;23:8629-35. (Pubitemid 46211505)
13. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005;23:7491-6. (Pubitemid 46291812)
14. Arnold AGA, Kauff ND. Prophylactic oophorectomy may differentially reduce breast cancer risk in women with BRCA1 versus BRCA2 mutations. Curr Breast Cancer Rep 2009;1:157-61.
15. Shah P, Rosen M, Stopfer J, Siegfried J, Kaltman R, Mason B, et al. Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence. Breast Cancer Res Treat 2009;118:539-46.
16. Groeneveld FP, Bareman FP, Barentsen R, Dokter HJ, Drogendijk AC, Hoes AW. The climacteric and well-being. J Psychosom Obstet Gynaecol 1993;14:127-43. (Pubitemid 23210668)
17. Fakkert IE, Jansen L, Meijer K, Kok T, Oosterwijk JC, Mourits MJ, et al. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy. Breast Cancer Res Treat 2011;129:157-64.
18. Zonderland H, Wagner T, van Asperen C, Benraadt J, de Bock GH, den Heeten GJ, et al. Richtlijn mammacarcinoom 2008 [Internet]. Utrecht: Kwaliteitsinstituut voor de gezondheidszorg CBO; 2008 [cited 2011 dec 13] Available from: http://www.cbo.nl/Downloads/328/rl-mamma-08.pdf.].
19. Kenkhuis MJ, de Bock GH, Elferink PO, Arts HJ, Oosterwijk JC, Jansen L, et al. Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. Maturitas 2010;66:310-4.
20. Kriege M, Brekelmans CT, Boetes C, Rutgers EJ, Oosterwijk JC, Tollenaar RA, et al. MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC). Fam Cancer 2001;1:163-8.
21. Tilanus-Linthorst MM, Kriege M, Boetes C, Hop WC, Obdeijn IM, Oosterwijk JC, et al. Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer 2005;41: 1610-7. (Pubitemid 40981844)
22. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006;295: 2374-84. (Pubitemid 43788105)
23. Liberman L, Mason G, Morris EA, Dershaw DD. Does size matter? Positive predictive value of MRI-detected breast lesions as a function of lesion size. AJR Am J Roentgenol 2006;186:426-30. (Pubitemid 46100312)
24. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26:1331-7.
25. Clarke RB. Ovarian steroids and the human breast: regulation of stem cells and cell proliferation. Maturitas 2006;54:327-34.
26. Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 2011;29:1664-9.
27. Dutch cancer figures, breast cancer incidence in 1989 and 2009 [Internet]. The Netherlands Cancer Registry; 2011 [cited 2011 Aug 28]. Available from: http://www.cijfersoverkanker.nl.
28. Junod B, Zahl PH, Kaplan RM, Olsen J, Greenland S. An investigation of the apparent breast cancer epidemic in France: screening and incidence trends in birth cohorts. BMC Cancer 2011;11:401.
29. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005;23:7804-10. (Pubitemid 46657377)
30. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008;100:1361-7.
31. Holmberg L, Iversen OE, Rudenstam CM, Kumpulainen E, Jaskiewicz J, Jassem J, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475-82.
32. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, noninferiority trial. Lancet Oncol 2009;10:135-46.
33. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ III. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006;7: 821-8. (Pubitemid 44464065)